Ceritinib

BreastfeedingPediatric
  • TRADE NAME: Zykadia (Novartis)
  • INDICATIONS: Anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer
  • CLASS: Tyrosine kinase inhibitor
  • HALF-LIFE: 41 hours

FDA APPROVAL DATE: 04/29/2014

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfentanil, Carbamazepine, Cyclosporine, CYP3A and CYP2C9 substrates, Dihydroergotamine, Ergotamine, Fentanyl, Grapefruit Juice, Ketoconazole, Nefazodone, Phenytoin, Pimozide, Quinidine, Rifampin, Ritonavir, Sirolimus, St John's Wort, Strong CYP3A inhibitors and inducers, Tacrolimus, Telithromycin, Warfarin

PREGNANCY CATEGORY: D

Our database has 40 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
OCULAR
OTHER


Page last updated 05/22/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric